Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Inflammation plays a role in Parkinson's disease (PD) pathogenesis and progression.
• Understanding the relationship between inflammatory markers and neurodegeneration is crucial for PD management.

Purpose of the Study:

• To investigate the association between 30 inflammatory markers in cerebrospinal fluid (CSF) and clinical/neurodegenerative aspects of Parkinson's disease (PD).
• To explore the predictive value of these markers for longitudinal cognitive impairment in PD patients.

Main Methods:

• Analysis of 30 inflammatory markers in CSF from 498 PD patients and 67 dementia with Lewy bodies (DLB) patients.
• Correlation of marker levels with clinical scores and CSF biomarkers (Aβ1-42, t-Tau, p181-Tau, NFL, α-synuclein).
• Longitudinal assessment of cognitive changes and association with baseline inflammatory marker levels.

Main Results:

• Specific inflammatory markers (ICAM-1, IL-8, MCP-1, MIP-1β, SCF, VEGF) correlated with clinical and neurodegenerative markers.
• No significant difference in inflammatory markers was observed between PD patients with and without GBA mutations.
• Higher baseline TNF-alpha levels were associated with the subsequent development of cognitive impairment.
• Elevated VEGF and MIP-1β levels correlated with a longer time to cognitive impairment onset.

Conclusions:

• Certain inflammatory markers show associations with clinical and neurodegenerative features in PD.
• Inflammatory markers have limited ability to robustly predict the long-term trajectory of cognitive impairment in PD.
• GBA mutation status does not appear to significantly alter inflammatory marker profiles in PD.